Literature DB >> 26185403

Ramucirumab (Cyramza): A Breakthrough Treatment for Gastric Cancer.

Amrita D Singh, Sapna Parmar.   

Abstract

Ramucirumab (Cyramza): A breakthrough treatment for gastric cancer.

Entities:  

Year:  2015        PMID： 26185403      PMCID： PMC4495869     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  11 in total

1.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Authors:  Josep Tabernero; Takayuki Yoshino; Allen Lee Cohn; Radka Obermannova; Gyorgy Bodoky; Rocio Garcia-Carbonero; Tudor-Eliade Ciuleanu; David C Portnoy; Eric Van Cutsem; Axel Grothey; Jana Prausová; Pilar Garcia-Alfonso; Kentaro Yamazaki; Philip R Clingan; Sara Lonardi; Tae Won Kim; Lorinda Simms; Shao-Chun Chang; Federico Nasroulah
Journal:  Lancet Oncol       Date:  2015-04-12       Impact factor: 41.316

2.  Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review.

Authors:  Hung-Yang Kuo; Kun-Huei Yeh
Journal:  Anticancer Res       Date:  2014-07       Impact factor: 2.480

3.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

4.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Authors:  Edward B Garon; Tudor-Eliade Ciuleanu; Oscar Arrieta; Kumar Prabhash; Konstantinos N Syrigos; Tuncay Goksel; Keunchil Park; Vera Gorbunova; Ruben Dario Kowalyszyn; Joanna Pikiel; Grzegorz Czyzewicz; Sergey V Orlov; Conrad R Lewanski; Michael Thomas; Paolo Bidoli; Shaker Dakhil; Steven Gans; Joo-Hang Kim; Alexandru Grigorescu; Nina Karaseva; Martin Reck; Federico Cappuzzo; Ekaterine Alexandris; Andreas Sashegyi; Sergey Yurasov; Maurice Pérol
Journal:  Lancet       Date:  2014-06-02       Impact factor: 79.321

5.  A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.

Authors:  Richard D Carvajal; Michael K Wong; John A Thompson; Michael S Gordon; Karl D Lewis; Anna C Pavlick; Jedd D Wolchok; Patrick B Rojas; Jonathan D Schwartz; Agop Y Bedikian
Journal:  Eur J Cancer       Date:  2014-06-12       Impact factor: 9.162

Review 6.  Vascular endothelial growth factor a inhibition in gastric cancer.

Authors:  Do Joong Park; Nicholas J Thomas; Changhwan Yoon; Sam S Yoon
Journal:  Gastric Cancer       Date:  2014-07-04       Impact factor: 7.370

7.  A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Authors:  Richard T Penson; Kathleen M Moore; Gini F Fleming; Patricia Braly; Veronica Schimp; Hoa Nguyen; Ursula A Matulonis; Susana Banerjee; Paul Haluska; Martin Gore; Diane C Bodurka; Rebecca R Hozak; Adarsh Joshi; Yihuan Xu; Jonathan D Schwartz; William P McGuire
Journal:  Gynecol Oncol       Date:  2014-07-10       Impact factor: 5.482

8.  Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

Authors:  Jennifer L Spratlin; Roger B Cohen; Matthew Eadens; Lia Gore; D Ross Camidge; Sami Diab; Stephen Leong; Cindy O'Bryant; Laura Q M Chow; Natalie J Serkova; Neal J Meropol; Nancy L Lewis; E Gabriela Chiorean; Floyd Fox; Hagop Youssoufian; Eric K Rowinsky; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

Review 9.  Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects.

Authors:  Omar Abdel-Rahman
Journal:  Crit Rev Oncol Hematol       Date:  2014-06-10       Impact factor: 6.312

10.  Gastric cancer: Classification, histology and application of molecular pathology.

Authors:  Bing Hu; Nassim El Hajj; Scott Sittler; Nancy Lammert; Robert Barnes; Aurelia Meloni-Ehrig
Journal:  J Gastrointest Oncol       Date:  2012-09
View more
  3 in total

1.  Cationic amino acid transporter PQLC2 is a potential therapeutic target in gastric cancer.

Authors:  Yun-Ji Jeung; Kyeong Lee; Hyo Jin Lee; Eunah Kim; Myung Jin Son; Jiwon Ahn; Han-Gyeul Kim; Wantae Kim; Ho-Joon Lee; Jin Man Kim; Kyung-Sook Chung
Journal:  Cancer Sci       Date:  2019-03-19       Impact factor: 6.716

Review 2.  Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches.

Authors:  Nehad M Ayoub; Sara K Jaradat; Kamal M Al-Shami; Amer E Alkhalifa
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

Review 3.  Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States.

Authors:  Marion Ferreira; Thomas Secher; Nathalie Heuze-Vourc'H; Karen L Reckamp
Journal:  Pharmaceutics       Date:  2021-06-21       Impact factor: 6.321
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.